Page 45 - Read Online

Kwee et al. Hepatoma Res 2021;7:8 I http://dx.doi.org/10.20517/2394-5079.2020.124 Page 11 of 13

REFERENCES
1. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from
1975 to 2005. J Clin Oncol 2009;27:1485-91.
2. Yarchoan M, Agarwal P, Villanueva A, et al. Recent developments and therapeutic strategies against hepatocellular carcinoma. Cancer
Res 2019;79:4326-30.
3. El-khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label,
non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-502.
4. Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib
(KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018;19:940-52.
5. Finn RS, Qin S, Ikeda M, et al; IMbrave150 Investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N
Engl J Med 2020;382:1894-905.
6. Finn RS, Ryoo B, Merle P, et al; for the KEYNOTE-240 Investigators. Results of KEYNOTE-240: phase 3 study of pembrolizumab
(Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC). JCO2019;37:4004.
7. Lee PC, Chao Y, Chen MH, et al. Predictors of response and survival in immune checkpoint inhibitor-treated unresectable hepatocellular
carcinoma. Cancers (Basel) 2020;12:182.
8. Ang C, Klempner SJ, Ali SM, et al. Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in
advanced hepatocellular carcinoma. Oncotarget 2019;10:4018-25.
9. Finn RS, Ryoo BY, Merle P, et al; KEYNOTE-240 investigators. Pembrolizumab as second-line therapy in patients with advanced
hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol 2020;38:193-202.
10. Shimada S, Mogushi K, Akiyama Y, et al. Comprehensive molecular and immunological characterization of hepatocellular carcinoma.
EBioMedicine 2019;40:457-70.
11. Pinyol R, Sia D, Llovet JM. Immune exclusion-Wnt/CTNNB1 class predicts resistance to immunotherapies in HCC. Clin Cancer Res
2019;25:2021-3.
12. Luke JJ, Bao R, Sweis RF, Spranger S, Gajewski TF. WNT/β-catenin pathway activation correlates with immune exclusion across human
cancers. Clin Cancer Res 2019;25:3074-83.
13. Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 2015;523:231-5.
14. Taube JM, Young GD, McMiller TL, et al. Differential expression of immune-regulatory genes associated with PD-L1 display in
melanoma: implications for PD-1 pathway blockade. Clin Cancer Res 2015;21:3969-76.
15. Ayers M, Lunceford J, Nebozhyn M, et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest
2017;127:2930-40.
16. Harding JJ, Nandakumar S, Armenia J, et al. Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation
sequencing for matching patients to targeted and immune therapies. Clin Cancer Res 2019;25:2116-26.
17. Spranger S, Gajewski TF. Impact of oncogenic pathways on evasion of antitumour immune responses. Nat Rev Cancer 2018;18:139-47.
18. Ou Q, Yu Y, Li A, et al. Association of survival and genomic mutation signature with immunotherapy in patients with hepatocellular
carcinoma. Ann Transl Med 2020;8:230.
19. Yaguchi T, Goto Y, Kido K, et al. Immune suppression and resistance mediated by constitutive activation of Wnt/β-catenin signaling in
human melanoma cells. J Immunol 2012;189:2110-7.
20. Spranger S, Dai D, Horton B, Gajewski TF. Tumor-residing Batf3 dendritic cells are required for effector T Cell trafficking and adoptive
T cell therapy. Cancer Cell 2017;31:711-23.e4.
21. Spranger S, Gajewski TF. A new paradigm for tumor immune escape: β-catenin-driven immune exclusion. J Immunother Cancer
2015;3:43.
22. Ruiz de Galarreta M, Bresnahan E, Molina-Sánchez P, et al. β-catenin activation promotes immune escape and resistance to anti-PD-1
therapy in hepatocellular carcinoma. Cancer Discov 2019;9:1124-41.
23. Calderaro J, Couchy G, Imbeaud S, et al. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular
tumour classification. J Hepatol 2017;67:727-38.
24. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006;127:469-80.
25. Audard V, Grimber G, Elie C, et al. Cholestasis is a marker for hepatocellular carcinomas displaying beta-catenin mutations. J Pathol
2007;212:345-52.
26. Nishida N, Nishimura T, Nagasaka T, Ikai I, Goel A, Boland CR. Extensive methylation is associated with beta-catenin mutations in
hepatocellular carcinoma: evidence for two distinct pathways of human hepatocarcinogenesis. Cancer Res2007;67:4586-94.
27. Kim G, Kurnit KC, Djordjevic B, et al. Nuclear β-catenin localization and mutation of the CTNNB1 gene: a context-dependent
association. Mod Pathol 2018;31:1553-9.
28. Gougelet A, Sartor C, Senni N, et al. Hepatocellular carcinomas with mutational activation of beta-catenin require choline and can be
detected by positron emission tomography. Gastroenterology 2019;157:807-22.
29. Senni N, Savall M, Cabrerizo Granados D, et al. β-catenin-activated hepatocellular carcinomas are addicted to fatty acids. Gut
2019;68:322-34.
30. Hart MJ, de los Santos R, Albert IN, Rubinfeld B, Polakis P. Downregulation of β-catenin by human Axin and its association with the
APC tumor suppressor, β-catenin and GSK3β. Current Biology 1998;8:573-81.
31. He X, Semenov M, Tamai K, Zeng X. LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling: arrows point the way.
Development 2004;131:1663-77.